---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035390"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:41:15.709383+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3

## Summary
- FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.
- Net loss of $14.6M vs. $18.0M in Q2 2023; cash and investments $78.6M as of June 30, 2024.
- Two-thirds interim analysis of fully enrolled PRECISION1 trial expected in Q3 2024.
- Enrollment ongoing in Phase 2 trials for endometrial cancer and neuroendocrine tumors.
- Cash runway expected to fund operations into Q4 2025 based on current plans.

## SEC filing metadata
- accession: 0001628280-24-035390
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/0001628280-24-035390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/aadi-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035390
- JSON: https://secwatch.observer/filing/0001628280-24-035390.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.